Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
This study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based chemotherapy regimen.
Non-small Cell Lung Cancer
DRUG: icotinib
progression-free survival, 6 months
overall survival, 12 months|objective response rate, 2 months|number of patients suffered adverse events, 15 months
This study was a single-arm, multi-center, prospective, phase 3 trial aimed to evaluate the efficacy and safety of icotinib in patients with locally advanced or metastatic NSCLC after failure of at least one platinum-based chemotherapy regimen.